The drugs Esperavir and Areplivir are included in the current treatment regimens for seasonal acute respiratory viral infections

16.12.2022

Medicines

The medicines Esperavir® and Areplivir® manufactured by Promomed Group, which were previously included in the approved regimens of targeted etiotropic therapy for COVID-19, are also recommended for patients with initial symptoms of acute respiratory viral infections in the 17th version of the interim guidelines for the prevention, diagnosis and treatment of new coronavirus infection (COVID-19).


In the updated guidelines, taking into account the similarity of the clinical symptoms of mild forms of coronavirus with seasonal acute respiratory viral infections,The Ministry of Health of the Russian Federation recommends Before confirming the established diagnosis and based on the clinical picture, include drugs based on molecules with direct antiviral action – molnupiravir and favipiravir - in the treatment regimens for viral diseases affecting the respiratory system. When prescribing, it is necessary to take into account the epidemiological history, the severity of the course of previously transmitted COVID-19 and other important criteria.

Get the most interesting news and publications first!

Sent successfully!

Pharmacovigilance

Press office

To request a press release or interview, please contact our press office